Journal
LUNG CANCER
Volume 80, Issue 1, Pages 1-4Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2012.12.019
Keywords
Adenocarcinoma; EGFR; Mutation; Neuroendocrine; NSCLC; SCLC
Categories
Funding
- Higher Education Funding Council for England
- NHS
Ask authors/readers for more resources
Several different acquired resistance mechanisms of EGFR mutant lung adenocarcinoma to EGFR-tyrosine kinase inhibitor (TKI) therapy have been described, most recently transformation to small cell lung carcinoma (SCLC). We describe the case of a 46-year-old female with relapsed EGFR exon 19 deletion lung adenocarcinoma treated with erlotinib, and on resistance, cisplatin-pemetrexed. Liver rebiopsy identified an afatinib-resistant combined SCLC and non-small cell carcinoma with neuroendocrine morphology, retaining the EGFR exon 19 deletion. This case highlights acquired EGFR-TKI resistance through transformation to the high-grade neuroendocrine carcinoma spectrum and that that such transformation may not be evident at time of progression on TKI therapy. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available